Number of shares
Holdings current value
% of portfolio
Daniel Loeb started to build up the position in Ventyx Biosciences in Q4 2021. Since then they sold 4.31 Million shares. The investor completely sold their stake between Q4 2022 and Q1 2023.
Ventyx is a classic example of Third Point’s ability to be lifecycle investors from early stages to IPO and beyond. Click here for our thesis on VTYX stock.
Easily embed the chart on your blog or website – it will always update